E-resources
Peer reviewed
Open access
-
Orandi, B. J.; Garonzik‐Wang, J. M.; Massie, A. B.; Zachary, A. A.; Montgomery, J. R.; Van Arendonk, K. J.; Stegall, M. D.; Jordan, S. C.; Oberholzer, J.; Dunn, T. B.; Ratner, L. E.; Kapur, S.; Pelletier, R. P.; Roberts, J. P.; Melcher, M. L.; Singh, P.; Sudan, D. L.; Posner, M. P.; El‐Amm, J. M.; Shapiro, R.; Cooper, M.; Lipkowitz, G. S.; Rees, M. A.; Marsh, C. L.; Sankari, B. R.; Gerber, D. A.; Nelson, P. W.; Wellen, J.; Bozorgzadeh, A.; Gaber, A. O.; Montgomery, R. A.; Segev, D. L.
American journal of transplantation, July 2014, Volume: 14, Issue: 7Journal Article
Incompatible live donor kidney transplantation (ILDKT) offers a survival advantage over dialysis to patients with anti‐HLA donor‐specific antibody (DSA). Program‐specific reports (PSRs) fail to account for ILDKT, placing this practice at regulatory risk. We collected DSA data, categorized as positive Luminex, negative flow crossmatch (PLNF) (n = 185), positive flow, negative cytotoxic crossmatch (PFNC) (n = 536) or positive cytotoxic crossmatch (PCC) (n = 304), from 22 centers. We tested associations between DSA, graft loss and mortality after adjusting for PSR model factors, using 9669 compatible patients as a comparison. PLNF patients had similar graft loss; however, PFNC (adjusted hazard ratio aHR = 1.64, 95% confidence interval CI: 1.15–2.23, p = 0.007) and PCC (aHR = 5.01, 95% CI: 3.71–6.77, p < 0.001) were associated with increased graft loss in the first year. PLNF patients had similar mortality; however, PFNC (aHR = 2.04; 95% CI: 1.28–3.26; p = 0.003) and PCC (aHR = 4.59; 95% CI: 2.98–7.07; p < 0.001) were associated with increased mortality. We simulated Centers for Medicare & Medicaid Services flagging to examine ILDKT's effect on the risk of being flagged. Compared to equal‐quality centers performing no ILDKT, centers performing 5%, 10% or 20% PFNC had a 1.19‐, 1.33‐ and 1.73‐fold higher odds of being flagged. Centers performing 5%, 10% or 20% PCC had a 2.22‐, 4.09‐ and 10.72‐fold higher odds. Failure to account for ILDKT's increased risk places centers providing this life‐saving treatment in jeopardy of regulatory intervention. In this 22‐center study of HLA‐incompatible live donor kidney transplants (ILDKT), the authors demonstrate the increased risk of graft loss and death associated with increasing anti‐HLA donor‐specific antibody strength, and they quantify the significantly increased risk of flagging for regulatory scrutiny by the Centers for Medicare & Medicaid Studies that is incurred by centers that perform ILDKT. See editorial by Cole and Tinckam on page 1475.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.